PT - JOURNAL ARTICLE AU - Lu, Fred S. AU - Nguyen, Andre T. AU - Link, Nicholas B. AU - Davis, Jessica T. AU - Chinazzi, Matteo AU - Xiong, Xinyue AU - Vespignani, Alessandro AU - Lipsitch, Marc AU - Santillana, Mauricio TI - Estimating the Cumulative Incidence of COVID-19 in the United States Using Four Complementary Approaches AID - 10.1101/2020.04.18.20070821 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.18.20070821 4099 - http://medrxiv.org/content/early/2020/08/07/2020.04.18.20070821.short 4100 - http://medrxiv.org/content/early/2020/08/07/2020.04.18.20070821.full AB - Effectively designing and evaluating public health responses to the ongoing COVID-19 pandemic requires accurate estimation of the prevalence of COVID-19 across the United States (US). Equipment shortages and varying testing capabilities have however hindered the usefulness of the official reported positive COVID-19 case counts. We introduce four complementary approaches to estimate the cumulative incidence of symptomatic COVID-19 in each state in the US as well as Puerto Rico and the District of Columbia, using a combination of excess influenza-like illness reports, COVID-19 test statistics, COVID-19 mortality reports, and a spatially structured epidemic model. Instead of relying on the estimate from a single data source or method that may be biased, we provide multiple estimates, each relying on different assumptions and data sources. Across our four approaches emerges the consistent conclusion that on April 4, 2020, the estimated case count was 5 to 50 times higher than the official positive test counts across the different states. Nationally, our estimates of COVID-19 symptomatic cases as of April 4 have a likely range of 2.2 to 4.9 million, with possibly as many as 8.1 million cases, up to 26 times greater than the cumulative confirmed cases of about 311,000. Extending our method to May 16, 2020, we estimate that cumulative symptomatic incidence ranges from 6.0 to 10.3 million, as opposed to 1.5 million positive test counts. The proposed combination of approaches may prove useful in assessing the burden of COVID-19 during resurgences in the US and other countries with comparable surveillance systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMS is partially supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R01GM130668. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available. https://www.census.gov/data/tables/time-series/demo/popest/2010s-state-detail.html https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html https://coronavirus.jhu.edu/data https://covidtracking.com/